 Edsa Biotech Inc. NASDAQ:EDSA shares are trading higher after the company announced Phase 2 Data of its Monoclonal Antibody in hospitalized COVID-19 patients. Critically ill patients demonstrated a 68.5 reduction in risk of dying when treated with EB05 over standard care. 